A Phase II Study of Plerixafor, Combined with G-CSF for CD34(+) Cell Mobilization in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Autologous Transplantation. Here, CSF3 is linked to AL amyloidosis.